Maria Luisa GarrÃ¨

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6728685/publications.pdf

Version: 2024-02-01

130	5,390	94433	95266
papers	citations	37 h-index	68 g-index

134	134	134	6760
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro-Oncology, 2013, 15, 788-796.	1.2	277
2	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
3	Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis. Journal of Clinical Oncology, 2010, 28, 4961-4968.	1.6	273
4	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	27.8	266
5	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	1.6	232
6	A Prospective Study on the Epidemiology of Febrile Episodes during Chemotherapy-Induced Neutropenia in Children with Cancer or after Hemopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 2007, 45, 1296-1304.	5.8	221
7	Medulloblastoma with extensive nodularity: a variant with favorable prognosis. Journal of Neurosurgery, 1999, 91, 971-977.	1.6	179
8	Identification of aSUFUgermline mutation in a family with Gorlin syndrome. American Journal of Medical Genetics, Part A, 2009, 149A, 1539-1543.	1.2	163
9	Outcome of patients with intracranial non-germinomatous germ cell tumorsâ€"lessons from the SIOP-CNS-GCT-96 trial. Neuro-Oncology, 2017, 19, 1661-1672.	1.2	150
10	Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. Cancer Cell, 2018, 33, 829-842.e5.	16.8	140
11	Craniopharyngioma: modern concepts in pathogenesis and treatment. Current Opinion in Pediatrics, 2007, 19, 471-479.	2.0	137
12	Recurrent noncoding U1ÂsnRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature, 2019, 574, 707-711.	27.8	129
13	Childhood medulloblastoma. Critical Reviews in Oncology/Hematology, 2016, 105, 35-51.	4.4	119
14	Apparent preferential loss of heterozygosity atTSC2 overTSC1 chromosomal region in tuberous sclerosis hamartomas. , 1996, 15, 18-25.		118
15	Medulloblastoma Variants: Age-Dependent Occurrence and Relation to Gorlin Syndromeâ€"A New Clinical Perspective. Clinical Cancer Research, 2009, 15, 2463-2471.	7.0	112
16	Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. Neuro-Oncology, 2016, 18, 1451-1460.	1.2	108
17	Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. Journal of Pediatrics, 1987, 111, 606-612.	1.8	95
18	Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1336-1345.	0.8	93

#	Article	IF	Citations
19	Stereotactically guided conformal radiotherapy for progressive low-grade gliomas of childhood. International Journal of Radiation Oncology Biology Physics, 2002, 53, 43-51.	0.8	91
20	Secreting germ cell tumors of the central nervous system (CNS). First results of the cooperative German/Italian pilot study (CNS sGCT). Klinische Padiatrie, 1997, 209, 222-227.	0.6	77
21	Low-grade gliomas and leptomeningeal dissemination: a poorly understood phenomenon. Child's Nervous System, 2003, 19, 197-203.	1.1	74
22	Magnetic resonance imaging spectrum of medulloblastoma. Neuroradiology, 2011, 53, 387-396.	2.2	69
23	The Diagnosis of Children with Central Diabetes Insipidus. Journal of Pediatric Endocrinology and Metabolism, 2007, 20, 359-75.	0.9	62
24	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	3.0	62
25	Childhood medulloblastoma. Critical Reviews in Oncology/Hematology, 2011, 79, 65-83.	4.4	58
26	Second malignant tumors after elective end of therapy for a first cancer in childhood: A multicenter study in Italy. International Journal of Cancer, 1994, 59, 451-456.	5.1	57
27	Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects. Cancer Letters, 2005, 228, 283-299.	7.2	53
28	New MR sequences (diffusion, perfusion, spectroscopy) in brain tumours. Pediatric Radiology, 2010, 40, 999-1009.	2.0	53
29	Medulloblastoma in young children. Pediatric Blood and Cancer, 2010, 54, 635-637.	1.5	52
30	Diagnostic and prognostic value of¹⁸F-DOPA PET and¹H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study. Neuro-Oncology, 2015, 17, 1637-1647.	1.2	49
31	Subtype-specific expression and genetic alterations of the chemokinereceptor geneCXCR4 in medulloblastomas. International Journal of Cancer, 2005, 117, 82-89.	5.1	47
32	Phase II trial of temozolomide in children with recurrent high-grade glioma. Journal of Neuro-Oncology, 2006, 77, 89-94.	2.9	47
33	Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. Neuro-Oncology, 2014, 16, 748-753.	1.2	47
34	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
35	Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer <scp>KU</scp>60019. International Journal of Cancer, 2015, 136, 1445-1457.	5.1	45
36	Value of ¹⁸F-3,4-Dihydroxyphenylalanine PET/MR Image Fusion in Pediatric Supratentorial Infiltrative Astrocytomas: A Prospective Pilot Study. Journal of Nuclear Medicine, 2014, 55, 718-723.	5.0	43

#	Article	IF	Citations
37	Pediatric astrocytic tumor grading: comparison between arterial spin labeling and dynamic susceptibility contrast MRI perfusion. Neuroradiology, 2018, 60, 437-446.	2.2	43
38	Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. Neuro-Oncology, 2012, 14, 1346-1356.	1.2	42
39	Advanced MR imaging and 18F-DOPA PET characteristics of H3K27M-mutant and wild-type pediatric diffuse midline gliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1685-1694.	6.4	41
40	Treatment and outcome of children with cerebral cavernomas: a survey on 32 patients. Neurological Sciences, 2010, 31, 117-123.	1.9	40
41	Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients. Cancer Chemotherapy and Pharmacology, 2003, 52, 459-464.	2.3	38
42	Second-look surgery for ependymoma: the Italian experience. Journal of Neurosurgery: Pediatrics, 2011, 8, 246-250.	1.3	38
43	High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma. Neuro-Oncology, 2011, 13, 500-508.	1.2	37
44	Supratentorial ependymoma in childhood: more than just RELA or YAP. Acta Neuropathologica, 2021, 141, 455-466.	7.7	37
45	A multimodal strategy based on surgery, radiotherapy, ICE regimen and high dose chemotherapy in atypical teratoid/rhabdoid tumours: a single institution experience. Journal of Neuro-Oncology, 2009, 92, 177-183.	2.9	36
46	Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960â€“1999 and registered in the Italian Off-Therapy Registry. European Journal of Cancer, 2019, 110, 86-97.	2.8	36
47	Multimodal Magnetic Resonance Imaging and ¹⁸F-L-Dihydroxyphenylalanine Positron Emission Tomography in Early Characterization of Pseudoresponse and Nonenhancing Tumor Progression in a Pediatric Patient With Malignant Transformation of Ganglioglioma Treated With Bevacizumab. Journal of Clinical Oncology, 2013, 31, e1-e5.	1.6	35
48	Natural history of cavernous malformations in children with brain tumors treated with radiotherapy and chemotherapy. Journal of Neuro-Oncology, 2014, 117, 311-320.	2.9	35
49	Expression and Functional Analysis of Human Leukocyte Antigen Class I Antigen-Processing Machinery in Medulloblastoma. Cancer Research, 2007, 67, 5471-5478.	0.9	33
50	Salvage treatment for childhood ependymoma after surgery only: Pitfalls of omitting â€œat onceâ€• adjuvant treatment. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1440-1445.	0.8	31
51	Infant Ependymoma in a 10-Year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) Experience With Omitted or Deferred Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 80, 807-814.	0.8	31
52	Epilepsy associated with supratentorial brain tumors under 3 years of life. Epilepsy Research, 2009, 87, 184-189.	1.6	27
53	Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma. Cancer Letters, 2008, 261, 235-243.	7.2	26
54	Ability of 18F-DOPA PET/CT and fused 18F-DOPA PET/MRI to assess striatal involvement in paediatric glioma. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1664-1672.	6.4	25

#	Article	IF	Citations
55	T2*-based MR imaging (gradient echo or susceptibility-weighted imaging) in midline and off-midline intracranial germ cell tumors: a pilot study. Neuroradiology, 2018, 60, 89-99.	2.2	25
56	Expression of pERK and pAKT in pediatric high grade astrocytomas: Correlation with YKL40 and prognostic significance. Neuropathology, 2012, 32, 133-138.	1.2	24
57	Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. Neuro-Oncology, 2021, 23, 848-857.	1.2	24
58	Cervico-medullary desmoplastic infantile ganglioglioma: An unusual case with diffuse leptomeningeal dissemination at diagnosis. Pediatric Blood and Cancer, 2005, 45, 986-990.	1.5	23
59	Radiation-Induced Moyamoya Syndrome in Children with Brain Tumors: Case Series and Literature Review. World Neurosurgery, 2020, 135, 118-129.	1.3	23
60	When and why is surgical revascularization indicated for the treatment of moyamoya syndrome in patients with RASopathies? A systematic review of the literature and a single institute experience. Child's Nervous System, 2018, 34, 1311-1323.	1.1	22
61	Genotype-Phenotype Correlations in Neurofibromatosis Type 1: A Single-Center Cohort Study. Cancers, 2021, 13, 1879.	3.7	21
62	Secondary acute promyelocytic leukemia with t(8;21) and t(9;22) at onset and loss of the philadelphia chromosome at relapse. Cancer Genetics and Cytogenetics, 1990, 47, 41-46.	1.0	18
63	A very rare cancer in Down syndrome: medulloblastoma. Epidemiological data from 13 countries. Journal of Neuro-Oncology, 2013, 112, 107-114.	2.9	18
64	Bilateral germinoma of the basal ganglia. Pediatric Blood and Cancer, 2008, 50, 177-179.	1.5	16
65	Successful isolation and long-term establishment of a cell line with stem cell-like features from an anaplastic medulloblastoma. Neuropathology and Applied Neurobiology, 2008, 34, 306-315.	3.2	16
66	Added value of diffusion weighted imaging in pediatric central nervous system embryonal tumors surveillance. Oncotarget, 2017, 8, 60401-60413.	1.8	16
67	Detection of Transplacental Melanoma Metastasis Using Quantitative PCR. Diagnostic Molecular Pathology, 2010, 19, 78-82.	2.1	15
68	Growth Hormone Treatment in Irradiated Children with Brain Tumors. Journal of Pediatric Endocrinology and Metabolism, 1997, 10, 41-9.	0.9	14
69	Claudinâ€6 is of Limited Sensitivity and Specificity for the Diagnosis of Atypical Teratoid/Rhabdoid Tumors. Brain Pathology, 2011, 21, 558-563.	4.1	14
70	Intradural Extramedullary Ependymoma with Leptomeningeal Dissemination: The First Case Report in a Child and Literature Review. World Neurosurgery, 2015, 84, 865.e13-865.e19.	1.3	14
71	Correlation of multimodal ¹⁸F-DOPA PET and conventional MRI with treatment response and survival in children with diffuse intrinsic pontine gliomas. Theranostics, 2020, 10, 11881-11891.	10.0	14
72	Congenital Leukemia: Persistent Spontaneous Regression in a Patient with an Acquired Abnormal Karyotype. Acta Haematologica, 1989, 81, 48-50.	1.4	13

#	Article	IF	Citations
73	Molecular fingerprinting reflects different histotypes and brain region in low grade gliomas. BMC Cancer, 2013, 13, 387.	2.6	13
74	Congenital Segmental Lymphedema in Tuberous Sclerosis Complex With Associated Subependymal Giant Cell Astrocytomas Treated with Mammalian Target of Rapamycin Inhibitors. Journal of Child Neurology, 2014, 29, NP54-NP57.	1.4	13
75	Pineal Germinoma in a Child with Interferon-Î³ Receptor 1 Deficiency. Case Report and Literature Review. Journal of Clinical Immunology, 2014, 34, 922-927.	3.8	13
76	New insights into central nervous system involvement in FOP: Case report and review of the literature. American Journal of Medical Genetics, Part A, 2015, 167, 2817-2821.	1.2	12
77	Atypical teratoid/rhabdoid tumor (ATRT) arising from the 3rd cranial nerve in infants: a clinical-radiological entity?. Journal of Neuro-Oncology, 2015, 124, 175-183.	2.9	12
78	Evolving role of myeloablative chemotherapy in the treatment of childhood brain tumours. Bone Marrow Transplantation, 2005, 35, S31-S34.	2.4	11
79	Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation. Journal of Neuro-Oncology, 2012, 109, 477-484.	2.9	11
80	18F-DOPA Uptake of Developmental Venous Anomalies in Children With Brain Tumors. Clinical Nuclear Medicine, 2016, 41, e351-e352.	1.3	11
81	Faithful animal modelling of human glioma by using primary initiating cells and its implications for radiosensitization therapy. Scientific Reports, 2018, 8, 14191.	3.3	11
82	Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study. Frontiers in Oncology, 2020, 10, 795.	2.8	11
83	Cerebellar medullomyoblastoma with melanotic tubular structures. Pediatric Blood and Cancer, 2008, 50, 183-185.	1.5	10
84	Role of highâ€dose chemotherapy (HDCT) in treatment of atypical teratoid/rhabdoid tumors (AT/RTs). Pediatric Blood and Cancer, 2010, 54, 647-648.	1.5	10
85	Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Research Protocols, 2019, 8, e11868.	1.0	10
86	Post-chemotherapy maturation of a pineoblastoma. Acta Neuropathologica, 2010, 119, 651-653.	7.7	9
87	Intracerebral schwannoma in a child. British Journal of Neurosurgery, 2010, 24, 306-308.	0.8	9
88	TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma. Oncotarget, 2016, 7, 47918-47926.	1.8	9
89	Expression of histone H3 cell cycle-related gene, Vimentin and MYC genes in pediatric brain tumors. A preliminary analysis showing the different malignant cell growth potential. Molecular Brain Research, 1992, 13, 273-275.	2.3	8
90	Epidemiology of Febrile Neutropenia in Children With Central Nervous System Tumor. Journal of Pediatric Hematology/Oncology, 2011, 33, e310-e315.	0.6	8

#	Article	IF	Citations
91	Atypical choroid plexus papilloma: spontaneous resolution of diffuse leptomeningeal contrast enhancement after primary tumor removal in 2 pediatric cases. Journal of Neurosurgery: Pediatrics, 2017, 20, 284-288.	1.3	8
92	New concepts in the treatment of brain tumors in very young children. Expert Review of Neurotherapeutics, 2006, 6, 489-500.	2.8	7
93	Gigantism with Pituitary Macroadenoma: An Unusual Variant of McCune-Albright Syndrome. Journal of Pediatric Endocrinology and Metabolism, 2009, 22, 177-9.	0.9	7
94	Pediatric intracranial ependymoma: correlating signs and symptoms at recurrence with outcome in the second prospective AIEOP protocol follow-up. Journal of Neuro-Oncology, 2018, 140, 457-465.	2.9	7
95	Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors. Frontiers in Oncology, 2021, 11, 660892.	2.8	7
96	Parental Imbalances Involving Chromosomes 15q and 22q May Predispose to the Formation of De Novo Pathogenic Microdeletions and Microduplications in the Offspring. PLoS ONE, 2013, 8, e57910.	2.5	7
97	Langerhans cell histiocytosis presenting as a lumbosacral intradural-extramedullary mass. Pediatric Radiology, 1996, 26, 731-733.	2.0	5
98	Late Persistent Increased Putaminal 18F-DOPA Uptake Following Ipsilateral Frontal Resection. Clinical Nuclear Medicine, 2015, 40, e451-e452.	1.3	5
99	Radiation-Induced Moyamoya Syndrome After Proton Therapy in Child with Clival Chordoma: Natural History and Surgical Treatment. World Neurosurgery, 2019, 123, 306-309.	1.3	5
100	Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol. Neuro-Oncology, 2022, 24, 467-479.	1.2	5
101	Case Report: The Emerging Role of Ring Chromosome 22 in Phelan-McDermid Syndrome With Atypical Teratoid/Rhabdoid Tumor: The First Child Treated With Growth Hormone. Frontiers in Neurology, 2021, 12, 741062.	2.4	5
102	Role of Dynamic Parameters of 18F-DOPA PET/CT in Pediatric Gliomas. Clinical Nuclear Medicine, 2022, 47, 517-524.	1.3	5
103	ins(6;1) in a patient with congenital leukemia. Cancer Genetics and Cytogenetics, 1989, 37, 19-22.	1.0	4
104	N-myc Oncogene amplification in a pediatric case of glioblastoma multiforme. Child's Nervous System, 1991, 7, 410-413.	1.1	4
105	Medulloblastoma in children: CT and MRI findings. Neuroradiology, 1996, 38, 352-359.	2.2	4
106	Genetic abnormalities and CNS tumors: report of two cases of ependymoma associated with Klinefelterâ€™s Syndrome (KS). Child's Nervous System, 2007, 23, 219-223.	1.1	3
107	Loss of 10q26.1â€“q26.3 in association with 7q34â€“q36.3 gain or 17q24.3â€“q25.3 gain predict poor outcome in pediatric medulloblastoma. Cancer Letters, 2011, 308, 215-224.	7.2	3
108	Congenital multifocal rhabdoid tumor: a case with peculiar biological behavior and different response to treatment according to location (central nervous system and kidney). Cancer Genetics, 2014, 207, 441-444.	0.4	3

#	Article	IF	Citations
109	Pediatric Craniospinal Irradiation with Conventional Technique or Helical Tomotherapy: Impact of Age and Body Volume on Integral Dose. Tumori, 2016, 102, 387-392.	1.1	3
110	Neuroendocrine late effects after tailored photon radiotherapy for children with low grade gliomas: Long term correlation with tumour and treatment parameters. Radiotherapy and Oncology, 2017, 125, 241-247.	0.6	3
111	Calcifications in diffuse leptomeningeal glioneuronal tumors: a case series. Quantitative Imaging in Medicine and Surgery, 2022, 12, 2985-2994.	2.0	3
112	Endothelial Dysfunction in Childhood Cancer Survivors: A Narrative Review. Life, 2022, 12, 45.	2.4	3
113	Constitutional chromosomal events at 22q11 and 15q26 in a child with a pilocytic astrocytoma of the spinal cord. Molecular Cytogenetics, 2014, 7, 31.	0.9	2
114	Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?. Cancers, 2022, 14, 2693.	3.7	2
115	Deep Venous Thrombosis Associated with Antiphospholipid Antibodies in an Adolescent after Exeresis of a Pilocytic Astrocytoma. Pediatric Neurosurgery, 1996, 25, 323-324.	0.7	1
116	Do we really need class 1 evidence results to give adjuvant radiation therapy to childhood intracranial ependymomas?. Child's Nervous System, 2009, 25, 641-642.	1.1	1
117	Distinctive Genetic Profile With IDH1, TP53, and MLH1 Mutations in a Radiationâ€Induced Anaplastic Astrocytoma. Pediatric Blood and Cancer, 2016, 63, 179-179.	1.5	1
118	Craniospinal Reduced Dose Radiotherapy After Myeoablative Chemotherapy with Peripheral Blood Stem Cells Rescue, in High Risk Medulloblastoma: Results of a Mono-Institutional Study in Italy. International Journal of Radiation Oncology Biology Physics, 2005, 63, S25.	0.8	0
119	PO-0875 Development of pituitary deficits after radiotherapy in pediatric patients after long follow-up.. Radiotherapy and Oncology, 2019, 133, S461-S462.	0.6	0
120	EP-1612 Radiation induced hypothyroidism in pediatric tumours of central nervous system. Radiotherapy and Oncology, 2019, 133, S869-S870.	0.6	0
121	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii102-ii102.	1.2	0
122	Epileptic Seizures and Supratentorial Brain Tumors in Children. , 2012, , 25-31.		0
123	Epileptic Seizures and Supratentorial Brain Tumors in Children. Pediatric Cancer, 2012, , 199-206.	0.0	0
124	MRI in an unusual case of congenital spinal mesenchymal proliferation. Neuroradiology, 1996, 38, S196-S199.	2.2	0
125	DIPG-27. Behavioral disturbances as underestimated presenting symptoms in children with Diffuse Intrinsic Pontine Glioma (DIPG). Neuro-Oncology, 2022, 24, i24-i24.	1.2	0
126	LGG-40. Growth hormone replacement in children on therapy with Vemurafenib for Low Grade Glioma. Neuro-Oncology, 2022, 24, i97-i97.	1.2	0

#	Article	IF	Citations
127	OTHR-22. Malignant mesothelioma (MM) as second cancer in childhood brain tumor survivors: the first child with neurofibromatosis type 2 and concurrent MM. Neuro-Oncology, 2022, 24, i151-i152.	1.2	0
128	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	1.2	0
129	LGG-34. Nephrological impact of BRAF inhibitors in a pediatric population of central nervous system tumors: a single institution experience. Neuro-Oncology, 2022, 24, i95-i96.	1.2	0
130	IMG-12. Transient atypical brain and spine MRI features after high-dose chemotherapy may represent clumps of CD34+ hematopoietic stem cells. Neuro-Oncology, 2022, 24, i79-i79.	1.2	0